Fireside Chat, Interview
Kate Ryder, Founder & CEO of Maven Clinic
- Maven intends to launch a menopause product in early 2023 following increased demand signals from clients and the client advisory board.
- The company estimates it has achieved only 5% of its goal to transform women's and family healthcare, with a long-term plan to serve every individual starting a family or in the early years of building a family through technology and local provider partnerships.
- Employers are projected to remain the primary sales channel for Maven, driven by the need to support healthy employees and address return-to-work challenges following childbirth.
- Maven plans to expand its service offerings from commercial populations to Medicaid recipients following its successful launch with commercial health plans.
- The organization anticipates that value-based maternity contracts will improve clinical outcomes while reducing costs associated with inflated U.S. healthcare expenses.
- Ongoing discussions with payers regarding gender, race, and health equity are expected to yield better outcomes, though the company characterizes this progress as inconsistent, described as "two steps forward, one step back."
- The scientific advisory board highlights a critical opportunity to leverage technology and top medical professionals to address gaps in women's health, noting this sector is significantly behind other healthcare segments.
- A shifting demographic pool of female entrepreneurs, angel investors, and venture capitalists is expected to increase financial support for women-led startups.